IPilogue

DECEMBER 3, 2021

As part of the course requirements, students were asked to write a blog on a topic of their choice. The justification for the prohibition is agreeable: fear of patent infringement should not deter medical practitioners from applying their exercise of skill and judgment (see Janssen v Mylan at para 53 ).

Intellectual Property Law 106

Intellectual Property Law Patent Infringement Intellectual Property Law 106

Patently-O

SEPTEMBER 26, 2022

Topics: Enablement / Written Description (All three are biotech / pharma): 3 Cases; Infringement (FDA Labeling): 1 Case; Anticipation (On Sale Bar): 1 Case; Double Patenting (Still the law?) Mylan Pharmaceuticals Inc. , Nathan Kelley (Perkins) is representing Mylan. Full Scope Enablement in Amgen Inc. Sanofi, No.

Patent Law 126

Patent Law Law Patent Invention 126

43(B)log

AUGUST 9, 2021

Scilex Pharmaceuticals Inc. 5, 2021) Scilex sells an FDA-approved, prescription-strength topical analgesic self-adhesive patch, ZTlido (lidocaine), which is allegedly often prescribed off-label, including for general neuropathic pain (e.g., This worked better: Mylan Laboratories, Inc. By contrast, JHP Pharmaceuticals, LLC v.

False Advertising 59

False Advertising Advertising Advertising Marketing 59

Fish & Richardson Trademark & Copyright Thoughts

FEBRUARY 7, 2022

Regeneron Pharmaceuticals, Inc., The most challenged patents relate to aflibercept, held by Regeneron and sold under the trade names Eylea® and Zaltrap®, and tocilizumab, held by Chugai Pharmaceutical Co. Denials of institution – particularly the extent to which they are reviewable – have long been a contentious topic for the PTAB.

Reporting 52

Reporting Art Invention Patent 52

Fish & Richardson Trademark & Copyright Thoughts

JANUARY 11, 2022

Semglee ® (Mylan (Viatris) / Biocon). Hulio ® (Mylan). Fulphila ® (Mylan/Biocon). Ogivri ® (Mylan). MYL-1402O (Mylan / Biocon). December 17, 2021. Samsung Bioepis / Biogen). Lucentis ®. Roche / Genentech). ranibizumab-nuna. September 17, 2021. No earlier than June 2022. insulin glargine-yfgn. July 28, 2021.

Litigation 52

Litigation Settlement Patent Marketing 52